Silo Pharma, Inc. Overview
Pro stress-test →Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company that develops novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. Its therapeutic programs target underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.
Strategic Profile
Pro stress-test →The company's portfolio includes SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist for PTSD and stress-induced anxiety, and SP-26, a ketamine implant candidate for fibromyalgia and chronic pain. Silo employs a crypto treasury strategy involving Bitcoin, Ethereum, Solana, and has engaged Fireblocks for digital asset custody.
Competitive Landscape
Pro stress-test →Silo competes in the psychedelic-assisted therapy and novel CNS drug development space with established biotech firms and emerging psychedelic medicine companies. Its niche focus on intranasal delivery systems and ketamine implants differentiates it, but the space includes better-capitalized competitors developing PTSD and pain therapeutics through traditional and novel mechanisms.
Industry Context
Silo Pharma, Inc. operates in Biopharmaceutical Development / Psychedelic-Assisted Medicine.
Key facts
Founded: 2010 · Headquarters: Sarasota, US · Employees: N/A · Revenue: N/A · Market cap: $4.98M